https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-30 09:22:442024-05-30 09:22:44Study on Treatment of Wilson Disease in Japan Published in Japanese Journal of Gastroenterology and Hepatology
https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-30 09:22:442024-05-30 09:22:44Study on Treatment of Wilson Disease in Japan Published in Japanese Journal of Gastroenterology and Hepatology
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-29 08:43:142024-05-29 08:43:14Resolution Therapeutics Announces Upcoming Scientific Presentations at EASL Congress 2024
https://www.optimumcomms.com/wp-content/uploads/2023/06/adcendo_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-29 08:09:252024-05-29 08:09:25Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-28 12:30:312024-05-29 09:04:06Novo Holdings portfolio company Numab Therapeutics announces Johnson & Johnson (‘J&J’) to acquire its wholly-owned subsidiary Yellow Jersey Therapeutics
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-28 10:33:352024-05-28 10:33:35Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-28 09:00:032024-05-28 09:00:03Resolution Therapeutics to Participate in the Jefferies Global Healthcare Conference
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-24 08:41:502024-05-24 08:41:50STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-23 14:17:122024-05-23 14:17:12Novo Holdings Boston office named a 2024 Best Place to Work by the Boston Business Journal
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-23 10:30:112024-05-23 10:30:11Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
https://www.optimumcomms.com/wp-content/uploads/2023/02/DelSiTech_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-23 08:11:152024-07-18 10:40:27Delsitech announces a major licensing agreement on drug delivery
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-22 09:40:192024-05-22 09:40:19Bacteria in our gut could play a role in cardiometabolic disease: A new initiative aims to find out
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neophare_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-22 08:43:162024-05-22 08:43:16NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
https://www.optimumcomms.com/wp-content/uploads/2023/02/Baselaunch_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-22 08:37:382024-05-22 08:37:38BaseLaunch announces a new partnership with AbbVie
https://www.optimumcomms.com/wp-content/uploads/2023/02/Pheon_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-21 08:34:532024-05-21 08:35:21Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-21 08:31:122024-05-21 08:31:12Novo Holdings and A.P. Moller Holding back CIRCTEC, a leader in pyrolysis for sustainable end-of-life tyre recycling, in a €150 million financing round
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-16 09:13:242024-05-16 09:13:24One in three people die due to atherosclerosis: A new initiative aims to find new ways to prevent itWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
